CMND · Clearmind Medicine Inc.
Market Cap
$3.04M
Shares
507,404
Volume · Oct 20
600
Avg daily vol (11 sessions)
34.67K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$6.00
Open$6.16
Day$5.91–6.36
52W close$5.72–3,424.00
Avg vol 30d43K
Short int2K · 0.4% float · 1.0d
Short vol17%
DataNov 2022–Oct 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$7.50M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+20,968.3%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
0.4%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−89%
below
Price vs 50-day avg
−37%
below
RSI (14)
34
neutral
MACD trend
Positive
52-week position
0%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−5%
trailing
6-month return
−90%
trailing
YTD return
−96%
this year
Relative strength
−98%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $10 › 200d $56 — 200d above 50d
Institutional flow
Accumulating
+20% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.36% of float · ▼ -58.5% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
6 holders — mid 3-yr range
Squeeze score
40
low risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
167%
annualized · 1-yr
Max drawdown
−100%
past year
ATR
10.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−89%
Bearish
Price vs 50-day avg
−37%
Bearish
RSI (14)
34
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $10 › 200d $56 — 200d above 50d
Institutional flow
Accumulating
+20% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.36% of float · ▼ -58.5% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
6 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $6
Now $6 · 0%
Range high $3,424
vs 200-day avg -89%
vs 50-day avg -37%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CMND
this stock
Clearmind Medicine Inc.
|
$3.04M | — | — | — | 0.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$127.73B | +10.7% | +46.2% | 29.4 | 1.8% |
|
MRNA
Moderna, Inc.
|
$90.58B | +669.4% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +1.3% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$64.50B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CMND | -8.3% | -5.2% | -89.8% | -6.8% | -95.9% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | -6.8% | -4.3% | -97.5% | -7.3% | -108.3% |